Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor

American Journal of Gastroenterology

Volumn 95, Issue 7, 2000, Pages 1681-1690

  Goldstein, Jay L ^a   Silverstein, Fred E ^b   Agrawal, Naurang M ^c   Hubbard, Richard C ^d   Kaiser, June ^d   Maurath, Clement J ^d   Verburg, Kenneth M ^d   Geis, G Steven ^d  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK MANAGEMENT; STOMACH MUCOSA; STOMACH OBSTRUCTION; STOMACH PERFORATION; UPPER GASTROINTESTINAL TRACT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PEPTIC ULCER; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SULFONAMIDES;

EID: 0033930616     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)00986-2     Document Type: Article

References (32)

1. 2 production. J Pharmacol Exp Ther. 283:1997;1069-1075.
2. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature. 321:1971;232-235.
3. Davies P., Bailey P.J., Goldenberg M.M., et al. The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol. 2:1984;335-357.
4. Needleman P., Turk J.L., Jakschik B.A., et al. Arachidonic acid metabolism. Annu Rev Biochem. 55:1986;69-102.
5. Smith W.L., DeWitt D.L. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol. 62:1996;167-215.
6. Xie W., Chipman J.G., Robertson D.L., et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 88:1991;2692-2696.
7. Kujubu D.A., Fletcher B.S., Varnum B.C., et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 266:1991;12866-12872.
8. O'Banion M.K., Sadowski H.B., Winn V., et al. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem. 266:1991;23261-23267.
9. Gierse J.K., Hauser S.D., Creely D.P., et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 305:1995;479-484.
10. Laneuville O., Breuer D.K., DeWitt D.L., et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 271:1994;927-934.
11. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs A meta-analysis . Ann Intern Med. 115:1991;787-796.
12. Garcia Rodriguez L.A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 343:1994;769-772.
13. Langman M.J.S., Weil J., Wainwright P., et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 343:1994;1075-1078.
14. MacDonald T.M., Morant S.V., Robinson G.C., et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure cohort study . Br Med J. 315:1997;1333-1337.
15. Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulcerations. Gut. 28:1987;527-532.
16. Wolfe M.M. NSAIDs and the gastrointestinal mucosa. Hosp Pract. 31:1996;37-44.
17. Singh G., Ramey D.R. NSAID-induced gastrointestinal complications The ARAMIS perspective - 1997 . J Rheumatol. 25:(suppl 51):1998;8-16.
18. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs A randomized, double-blind, placebo-controlled trial . Ann Intern Med. 123:1995;241-249.
19. Penning T.D., Talley J.J., Bertenshaw S.R., et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors Identification of 4-[5-(4-methylphenyl)-3-(trifluromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib) . J Med Chem. 40:1997;1347-1365.
20. Simon L.S., Lanza F.L., Lipsky P.E., et al. Preliminary study of the safety and efficacy of SC-58635, a novel COX-2 inhibitor. Arthritis Rheum. 41:1998;1591-1602.
21. Simon L.S., Weaver A.L., Graham D.Y., et al. The anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis A randomized, controlled trial . JAMA. 282:1999;1921-1928.
22. Bensen W.G., Fiechtner J.J., McMillen J.I., et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor A randomized controlled trial . Mayo Clin Proc. 74:1999;1095-1105.
23. Williams G.W., Ettlinger R.E., Ruderman E.M., et al. Treatment of osteoarthritis with a once-daily regimen of celecoxib A randomized controlled trial . J Clin Rheumatol. 6:2000;65-74.
24. Emery P., Zeidler H., Kvien T.K., et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis Randomised double-blind comparison . Lancet. 354:1999;2106-2111.
25. Gutthann S.P., Garcia Rodriguez L.A., Raiford D.S. Individual nonsteroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology. 8:1997;18-24.
26. Borda I.T. The spectrum of adverse gastrointestinal effects associated with nonsteroidal anti-inflammatory drugs. Borda I.T., Koff R.S. NSAIDs A profile of adverse effects . 1992;25-79 Hanley and Belfus, Philadelphia.
27. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer disease. Br Med J. 310:1995;827-830.
28. Kelly J.P., Kaufman D.W., Jurgelon J.M. Risk of aspirin-associated major upper gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 348:1996;1413-1416.
29. Cullen D.J.E., Hawkey G.M., Greenwood D.C., et al. Peptic ulcer bleeding in the elderly Relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs . Gut. 41:1997;459-462.
30. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: Where we stand. Am J Gastroenterol 1996;91;10:2080-6.
31. Simon L.S. Biologic effects of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol. 9:1997;178-182.
32. Leese P.T., Hubbard R.C., Karim A., et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults A randomized, controlled trial . J Clin Pharmacol. 40:2000;124-132.